Medication Ototoxicity Checker

Cisplatin is one of the most ototoxic drugs in clinical use. It damages the outer hair cells of the cochlea, particularly affecting high-frequency hearing first. Hearing loss is dose-dependent and cumulative, meaning it worsens with each treatment cycle. Audiological monitoring before and during treatment is strongly recommended.

Carboplatin is related to cisplatin and shares similar ototoxic properties, though it is generally considered less ototoxic at standard doses. Children are at particularly high risk. Hearing loss typically begins in the high-frequency range and may progress to lower frequencies with continued treatment.

Gentamicin is an aminoglycoside antibiotic that is particularly toxic to the vestibular system, causing balance problems, dizziness, and vertigo. It can also damage the cochlea, leading to hearing loss. Risk increases with higher doses, longer treatment, and impaired kidney function. Serum levels should be monitored closely.

Tobramycin is an aminoglycoside antibiotic that can cause permanent damage to the hair cells of the inner ear. Both cochlear (hearing) and vestibular (balance) systems may be affected. Monitoring kidney function and drug levels helps reduce risk.

Amikacin primarily affects cochlear hair cells, with hearing loss typically starting at high frequencies. It is considered one of the more cochleotoxic aminoglycosides. Patients with kidney impairment or those receiving prolonged courses are at greatest risk.

Streptomycin was one of the first antibiotics recognized as ototoxic. It has a strong tendency to damage the vestibular system, causing problems with balance and spatial orientation. Cochlear damage and hearing loss can also occur, especially with prolonged use.

Neomycin is considered one of the most ototoxic aminoglycosides when absorbed systemically. While it is commonly used topically (ear drops, skin creams), systemic absorption through damaged skin or mucous membranes can lead to hearing loss. It should never be used in patients with perforated eardrums without medical guidance.

Vancomycin alone has a relatively low ototoxic potential, but the risk increases significantly when it is used in combination with aminoglycoside antibiotics. High trough levels and impaired kidney function are additional risk factors. Regular hearing monitoring is recommended during extended treatment.

Furosemide is a loop diuretic that can cause hearing loss, especially when given intravenously at high doses or rapid infusion rates. The ototoxic effect is related to changes in the fluid and electrolyte balance of the inner ear. Risk is significantly increased when furosemide is used alongside aminoglycoside antibiotics.

Ethacrynic acid is considered the most ototoxic of the loop diuretics. It can cause sudden, severe hearing loss that may be permanent. Because of this risk, it is generally reserved for patients who cannot tolerate other diuretics. The risk is compounded when used with other ototoxic medications.

High-dose aspirin (typically more than 6-8 tablets per day) can cause tinnitus and temporary hearing loss. This is one of the most well-known and predictable ototoxic effects in medicine. The good news is that these effects almost always resolve completely once the dose is reduced or the medication is stopped.

Regular, high-dose use of ibuprofen over extended periods has been associated with an increased risk of hearing loss in some studies. Occasional use at recommended doses is generally considered safe. If you take ibuprofen frequently and notice any hearing changes, discuss alternatives with your doctor.

Like other NSAIDs, naproxen may contribute to hearing changes when used regularly at high doses over long periods. The risk is relatively low at standard recommended doses. Patients who already have hearing loss should discuss long-term NSAID use with their healthcare provider.

Quinine is well-known for causing a collection of symptoms called "cinchonism" which includes tinnitus, hearing loss, dizziness, and headache. These effects are dose-dependent and typically reversible after discontinuation. Quinine is found not only in antimalarial drugs but also in tonic water, though in much smaller amounts.

Chloroquine can cause sensorineural hearing loss that may be irreversible in some cases, particularly with long-term use. It affects the inner ear by damaging the sensory hair cells. Patients taking chloroquine for extended periods should have regular hearing assessments.

Hydroxychloroquine is widely used for autoimmune conditions like lupus and rheumatoid arthritis. While ototoxicity is less common than with chloroquine, tinnitus and hearing changes have been reported, particularly with long-term use. Report any hearing changes to your doctor promptly.

Erythromycin can cause hearing loss when given at high doses intravenously, particularly in patients with kidney or liver impairment. The hearing loss is typically reversible once the drug is discontinued or the dose is reduced. Oral doses at standard levels carry much lower risk.

Azithromycin-related hearing loss is rare but has been documented, particularly at higher doses or in patients with pre-existing hearing conditions. Standard short courses (Z-Pack) are generally considered low-risk. Any hearing changes during treatment should be reported to your doctor.

Bumetanide is a loop diuretic similar to furosemide. It can cause temporary hearing changes, especially at high intravenous doses. The risk increases when combined with other ototoxic medications such as aminoglycosides. Hearing changes are usually reversible when the dose is adjusted.

Torsemide has a lower ototoxic potential compared to other loop diuretics like furosemide or ethacrynic acid, but hearing changes can still occur at high doses. It is generally considered a safer alternative within this drug class for patients concerned about hearing.

Methotrexate is used in chemotherapy and for autoimmune conditions. Ototoxicity is uncommon but has been reported, particularly at high doses used in cancer treatment. When hearing changes do occur, they are typically mild and reversible. Regular monitoring is still recommended during high-dose therapy.

5-Fluorouracil (5-FU) is a chemotherapy drug with a low risk of ototoxicity. Hearing changes are rare and typically mild. However, when used in combination with other potentially ototoxic chemotherapy agents, the combined risk may be higher.

Chronic overuse of hydrocodone-containing pain medications has been linked to sudden sensorineural hearing loss in some cases. This is not typically seen with short-term prescribed use. The exact mechanism is not fully understood, but it may involve reduced blood flow to the cochlea.

ACE inhibitors are commonly prescribed blood pressure medications. Tinnitus is a very rare side effect, occurring in a small percentage of patients. If tinnitus develops, it typically resolves after switching to a different blood pressure medication. These drugs are generally considered safe from an ototoxicity standpoint.

Beta blockers are widely used for high blood pressure, heart conditions, and anxiety. Tinnitus has been reported rarely. The mechanism is not well understood but may be related to changes in blood flow. In most cases, switching to a different medication resolves the issue.